FDA slaps hold on trials of Gilead’s CD47 drug magrolimab
pharmaphorum
JANUARY 26, 2022
It covers three phase 3 trials involving subjects with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), as well as ‘unfit’ AML patients who are unable to be treated with intensive treatment like high-dose chemotherapy.
40 
Let's personalize your content